5、消化系统肿瘤消化系统肿瘤 (19).pdf

《5、消化系统肿瘤消化系统肿瘤 (19).pdf》由会员分享，可在线阅读，更多相关《5、消化系统肿瘤消化系统肿瘤 (19).pdf（5页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、 Journal of Clinical Oncology List of Issues Volume 37,Issue 4_suppl Meeting Abstract|2019 Gastrointestinal Cancers SymposiumCANCERS OF THE PANCREAS,SMALL BOWEL,AND HEPATOBILIARY TRACTEfficacy and safety of dabrafenib(D)andtrametinib(T)in patients(pts)with BRAFV600Emutated biliary tract cancer(BTC):

2、Acohort of the ROAR basket trial.Rights&PermissionsArticlehas analtmetricscore of 13OPTIONS&TOOLSExport CitationTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article ToolsZev A.Wainberg,Ulrik Niels Lassen,Elena Elez,Antoine Italiano,Gius

3、eppeCurigliano,Filippo G.De Braud,.Show MoreAbstract Disclosures187Background:BTCs are rare,aggressivemalignancies with poor prognoses.Treatmentoptions and outcomes after first-line therapy arenot well defined.Median progression-free survival(PFS)in second-line BTC is 5 mo.Combined BRAF+MEK inhibiti

4、on is efficacious in BRAF V600mutated anaplastic thyroid cancer,melanoma,and lung cancer,but less so in BRAF V600E-mutated colorectal cancer.Activating BRAF V600Emutations have been reported in 0%to 20%ofBTCs;thus,D(BRAF inhibitor)+T(MEK inhibitor)was evaluated as a treatment for pts with BRAFV600Em

5、utated BTC in the ROAR basket trial.COMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2019.37.4_suppl.187Journal of Clinical Oncology 37,no.4_suppl(February 01,2019)187-187.Published online January 29,2019.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Emplo

6、yer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland

7、 Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractBRAF/ME

8、K Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick,The ASCO Post,2019BRAF/MEK Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick et al.,Hepatobiliary Cancer,2019Encorafenib Plus Cetuximab as aNew Standard of Care for PreviouslyTreated BRAF V600

9、EMutantMetastatic Colorectal Cancer:Updated Survival Results andSubgroup Analyses from theBEACON StudyJosep Tabernero et al.,J Clin Oncol,2021The Right Treatment for the RightTargets in BRAF-Mutant MetastaticMethods:In this phase II,open-label trial,pts withBRAF V600E mutations in 9 rare tumor types

10、,including BTC,received D(150 mg BID)+T(2 mgQD)until unacceptable toxicity,diseaseprogression,or death.Eligible pts had advancedor metastatic cancer and had been treated with 1 prior systemic therapy.The primary endpointwas investigator-assessed overall response rate(ORR).Secondary endpoints include

11、d duration ofresponse(DOR),PFS,overall survival(OS),biomarker correlates,and safety.Results:Thirty-three pts with BTC had enrolled at data cutoff(January 3,2018).BRAF V600E mutations werecentrally confirmed in 30 of 33 pts with BTC(91%).Median age was 58 y,and 78%had received 2prior lines of systemi

12、c therapy.32 of 33 pts withBTC were evaluable.Investigator-assessed ORRwas 41%(13/32;95%CI,24%-59%),with 6 of 13responses ongoing at data cutoff,7 of 13 pts(54%)had a DOR 6 mo.Median PFS was 7.2 mo(95%CI,4.6-10.1 mo),and median OS was 11.3 mo(95%CI,7.3-17.6 mo).Grade 3/4 adverse events in 3pts were

13、increased-glutamyltransferase(n=3ADVERTISEMENTCRCAlberto Puccini et al.,ASCO DailyNews,2019Heinz-Josef Lenz,MD,on BRAFV600EMutated Biliary Tract Cancer:Results From the ROAR Basket TrialHepatobiliary Cancer1 MILO/ENGOT-OV11:Phase-3 studyof binimetinib versus physicianschoice chemotherapy(PCC)inrecur

14、rent or persistent low-gradeserous carcinomas of the ovary,fallopian tube,or primaryperitoneumR Grisham et al.,InternationalJournal of Gynecologic Cancer,2019Association of BRAF V600E/KMutation Status and Prior BRAF/MEKInhibition With PembrolizumabOutcomes in Advanced Melanoma:Pooled Analysis of 3 C

15、linical TrialsIgor Puzanov et al.,JAMA Oncology,2020Vemurafenib for BRAF V600MutantErdheim-Chester Disease andLangerhans Cell Histiocytosis:Analysis of Data From the Histology-Independent,Phase 2,Open-labelVE-BASKET StudyEli L.Diamond et al.,JAMA Oncology,2018281 Real-world-data on platinumoutcomes

16、after parp inhibitorsprogression in high grade serousovarian cancer patientsAndrea Plaja Salarich et al.,International Journal of Gynecologic9%)and decreased white blood cell count(n=3pts 9%).Biomarker analyses demonstrate aheterogeneous genetic landscape,and suggest ahigher baseline expression of M

17、APK pathwaygenes in the pts who did not respond to D+T.Conclusions:D+T demonstrated promisingefficacy in pts with BTC,with a favorable safetyprofile.These pts should be considered for BRAFmutation analysis,and D+T should be consideredfor pts with BRAF V600E-mutated BTC.Clinical trialinformation:NCT0

18、2034110.2019 by American Society of Clinical OncologyCancer,2020Camrelizumab plus gemcitabine andoxaliplatin(GEMOX)in patients withadvanced biliary tract cancer:asingle-arm,open-label,phase II trialXiaofeng Chen et al.,Jitc,2020Powered byQUICK LINKSContentNewest Articles Archive Meeting AbstractsJou

19、rnal InformationAbout Editorial Roster ResourcesAuthors Reviewers Subscribers Institutions AdvertisersSubmit Your ManuscriptSubscribe to this JournalASCO FAMILY OF SITESJournalsJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncolo

20、gyPublicationsEducationASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center Contact Us PermissionsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology2318 Mill Road,Suite 800,Alexandria,VA 22314 2021 American Society of Clinical Oncology Terms of Use|Privacy Policy|Cookies